Evidence map›Paper›PMID 35377729›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?

Rahul Lakhotia, Christopher Melani, Mark Roschewski, Wyndham H Wilson

Open access · bronzeAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Rahul LakhotiaRahul Lakhotia, MBBS, Christopher Melani, MD, Mark Roschewski, MD, and Wyndham H. Wilson, MD, PhD, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.ORCID 0000-0003-3123-6844
Christopher MelaniRahul Lakhotia, MBBS, Christopher Melani, MD, Mark Roschewski, MD, and Wyndham H. Wilson, MD, PhD, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-9661-4570
Mark RoschewskiRahul Lakhotia, MBBS, Christopher Melani, MD, Mark Roschewski, MD, and Wyndham H. Wilson, MD, PhD, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.ORCID 0000-0003-0278-2635
Wyndham H WilsonRahul Lakhotia, MBBS, Christopher Melani, MD, Mark Roschewski, MD, and Wyndham H. Wilson, MD, PhD, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-2862-9711
National Cancer Institute · US

Funding

Therapeutic Strategies and Molecular Correlates in Aggressive B-cell LymphomasZIASC006741 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI WILSON, WYNDHAM H · 2009 to 2025
$10.4M
Targeted treatment of B-cell LymphomaZIABC011354 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WILSON, WYNDHAM H · 2010 to 2025
$4.6M
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lymphoma, B-CellLymphoma, Large B-Cell, DiffuseAdultAntineoplastic Combined Chemotherapy ProtocolsChildCyclophosphamideDoxorubicinEtoposideHumansPrednisoneRituximabVincristineCyclophosphamideDoxorubicinEtoposidePrednisoneRituximabVincristine

Identifiers

PMID35377729
PMCPMC9197344
OpenAlexW4226064077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.